Heron Therapeutics, Inc. (HRTX)

2,8400 +0,2300 (+8,81 %) À la clôture : 04:00PM EDT

Heron Therapeutics, Inc.

4242 Campus Point Court
Suite 200
San Diego, CA 92121
United States
858 251 4400
https://www.herontx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 126

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Craig Alexander Collard	CEO & Director	5,49k	S.O.	1966
Ms. Ira Duarte	Executive VP & CFO	636,89k	S.O.	1969
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer	734,62k	S.O.	1962
Mr. Ryan Craig	Vice President of Marketing	S.O.	S.O.	S.O.
Mr. Sean T. Ristine	Senior Vice President of Human Resources	S.O.	S.O.	1970
Mr. Robert Sullivan	Senior VP of Oncology Care Franchise & Commercial Operations	S.O.	S.O.	1978
Jeff Cohn	Executive Director, Assistant General Counsel & Assistant Secretary	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Heron Therapeutics, Inc. en date du 1 mai 2024 est 2. Les scores principaux sont Audit : 8; Société : 4; Droits des actionnaires : 1; Compensation : 5.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.